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Abstract
Fecal microbiota transplantation (FMT) is a method of transferring feces from an individual with a healthy microbiome to a patient 
whose healthy gut bacteria is deficient. While this method is not a new one, it is constantly being explored and studied to determine 
if it can be an effective way to treat patients with different bowel diseases . The main target of most of these studies are patients 
with recurrent Clostridium difficile infections.  Many studies were done to determine if the method is safe, and which method is most 
effective, as well as who can be a good donor or recipient of the treatment .
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Introduction
The large intestine is comprised of the cecum, the colon, 
the rectum and the anal canal. The colon is the last step in 
the digestive tract before the feces are expelled through 
the anus in a bowel movement. It is a tube-like structure 
containing the usual four layers; the mucosa, submucosa, 
muscularis and serosa. Problems can occur if the mucosa 
becomes inflamed or infected. Bacteria colonize the large 
intestine and aid in the digestion of proteins and other 
food particles to ready them for defecation. Bacteria also 
play a role in the homeostasis of the gut (Tortora, 2014).
The colon is packed with bacteria that make up the 
human microbiome. These are symbiotic organisms that 
perform different functions in the human body. Research 
has shown that many are important for metabolism and 
epithelial cell growth, doing jobs that are similar to those of 
the endocrine system. It seems that the microbial diversity 
turns out to be significantly higher in adults than children, 
and even more so in that of the elderly.  Infants are found 
to have an extremely low diversity. (Blaut, et al., 2002)
The many commensal bacteria in the gut influence im-
mune function. There are a few different ways this could 
be true. One of these is that the bacteria can promote 
the health of the epithelial lining in the intestines. This 
strengthens the primary barrier, so that pathogens can-
not pass through the lining. In addition, some of these 
good bacteria can help produce and secrete an anti-in-
flammatory response to some inflammatory cytokines. 
Other mechanisms include the production of secondary 
bile acids, and the competition for nutrients with the 
pathogenic bacteria (Zeng et al., 2019).
In people with a healthy gut composition, there are a 
different kind of bacteria that contribute to the symbiosis 
of the gut. These bacteria serve as an anatomical barrier to 
the different pathogens that enter the intestines through 
various ways such as with food that is ingested. The four 
main phyla that are found are Firmicutes, Bacteroides, 
Proteobacteria and Actinobacteria. (Lopetuso et al., 2013). 
In a normal bacterial gut composition, there is a sym-
biosis in which the bacteria work together to perform 
different functions. Dysbiosis occurs when there is an 
imbalance of the different gut bacteria, often resulting in 
disease such as inflammatory bowel diseases (IBD), and 
other gastrointestinal disorders. One common disease 
is infectious colitis caused by C. difficile. Others include 
gastritis, peptic ulcer, irritable bowel syndrome (IBS) and 
even gastric and colon cancer.  (Lopetuso et al., 2013).
Methods
Research for this paper included using databases such as 
the Touro College Library, PubMed and Google Scholar. 
These were used to find peer reviewed articles on stud-
ies related to gastrointestinal diseases and FMT as a 
treatment.
What is C. Difficile Infection?
As a result of taking antibiotics, many patients are left 
with a decrease in gut bacteria diversity, namely of the 
commensal Bacteroidetes and Firmicutes variety. At the 
same time, there tends to be a proliferation of proteo-
bacteria which include pathogenic organisms such as C. 
difficile and shigella (Staley et al., 2016). C. difficile, an op-
portunistic organism can now cause infection because it 
is not outcompeted by good bacteria for nutrients and 
other factors that help bacteria thrive. In addition, as 
mentioned above, there is a reduction in the bacteria that 
normally prevent the proliferation of these pathogens by 
different mechanisms. In the majority of cases, C. diffi-
cile is treated with the antibiotic vancomycin or other 
similar drugs. Often, this course of antibiotic therapy is 
ineffective, resulting in recurrent C. difficile infections. 
Fecal microbiota transplantation attempts to address the 
problem by allowing the feces of the healthy donor to aid 
in replenishing the depleted gut bacteria of the patient. 
This leads to the patient’s stool bacteria becoming very 
similar to that of the healthy donor (Kelly et al., 2015).
Secondary Bile Acid Production by Bacteria
There is evidence that suggests that secondary bile acid 
production is a crucial factor in preventing C. difficile infec-
tions. There appears to be a difference in the bile acid com-
position in the colon of patients with C. difficile infections 
in comparison to those with a healthy gut composition. A 
bile acid analysis study was done on fecal extracts of both 
donors and recipients of FMT. The results demonstrated 
that the pre-FMT samples contained mainly primary bile 
acids and bile acid salts and did not contain any secondary 
bile acids. In contrast, the post-FMT samples, as well as the 
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donor samples contained a high abundance of secondary 
bile acids, indicating that the bacteria from the healthy 
donor had an effect on secondary bile acid production. 
These factors seem to indicate that it is indeed the met-
abolic function of these bacteria that aid in preventing C. 
difficile infections (Weingarden et al., 2014). 
Primary bile acids are produced in the liver. The main 
ones are cholic acid and chenodeoxycholic acid. Before 
being secreted into bile, the bile acids are chemically at-
tached to the amino acids taurine and glycine to form bile 
salts. These are then secreted into bile and then used for 
lipid digestion in the small intestines. While most of these 
are reabsorbed, about 5% of them reach the large intestine 
where they subsequently become deoxycholic and litho-
cholic acids which are secondary bile acids. As mentioned 
before, post FMT and donor samples contained mainly sec-
ondary bile acids and few primary bile acids. Some studies 
have inferred that the primary bile acid taurocholic acid 
(cholic acid combined with taurine), is actually a require-
ment for C. difficile growth and proliferation, and is used 
in growth media for this organism. It was also noted that 
the secondary bile acids lithocholic and ursodeoxycholic 
acids (from chenodeoxycholic acids), inhibit the growth of 
C. difficile (Weingarden et al., 2014). 
In a study done, it became apparent that the Clostridium 
scindens, of the firmicutes phylum, is the bacteria that is 
likely responsible for preventing infection due to its role 
in secondary bile acid production (Staley et al., 2016).
The bile acid experiment was done in conjunction with 
the bacterial diversity survey. There was a correlation be-
tween the two studies, showing that an increase of second-
ary bile acids came along with an increase in Bacteroides 
and Firmicutes. These experiments indicate that it is likely 
these commensal bacteria play a metabolic role in bile acid 
production, inhibition of the pathogenic C. difficile, and 
overall gut health (Weingarden et al., 2014). 
Who is a Good Fecal Donor?
It is not completely clear who makes a good donor for 
FMT. It is assumed that it would greatly depend on the 
donor’s lifestyle and diet. Though it was noted during one 
study that there were good outcomes from one donor 
in particular, it was hard to trace exactly what made 
that donor so effective. In addition, many FMT trials are 
done with multi-donor stools for increased diversity. 
This would cause the researchers to be unable to isolate 
which donor made it most effective (Quraishi et al, 2017). 
There is indication that relatives are beneficial as FMT 
donors because they share genetics, and are likely to have a 
similar microbiome to the patient. Others say that it is ben-
eficial for a patient to receive FMT from his or her spouse 
because they likely have been in contact with similar patho-
gens and therefore may be protected from harmful effects 
of introducing many new bacteria to the gut. Some think 
that an unrelated donor is better, because they feel that 
someone who is not related would be more honest in an-
swering questions that may rule them out from donating. 
There is not enough conclusive evidence to determine if 
any of these are indeed true (Kelly et al, 2015).
In gathering the donors, there is a list of exclusion 
factors that can rule out those who should not donate 
stool. These include those who have been on antibi-
otics in the past 3 months, have had any history of a 
disease that is normally transmitted by stool, or who 
are known to have IBD, IBS or other gastrointestinal 
complications or conditions. In addition, those who have 
had a history of autoimmune diseases, malignant diseas-
es, chronic pain or metabolic syndromes cannot donate 
feces. The reason for this is because it is assumed that 
people who have these conditions may have an altered 
microbiome which might be detrimental to introduce 
to a patient who is already compromised (Kelly et al, 
2015). In addition, someone who has an autoimmune 
disease is likely being treated with immunosuppressants 
which suppresses the body’s immune system. If this was 
introduced into the recipient, this could be especially 
harmful because there is already an infection in the pa-
tient that needs to be treated, and they must have an 
active immune system. Additionally, it is possible that 
certain DNA which causes these conditions would be 
present in the stool and it would be very risky to in-
troduce to the patient (Petrov, M. E., 2011).  Once they 
have fulfilled the above requirements, they are screened 
for infections within a month of donating and can then 
donate stool (Kelly et al, 2015).
Screening Before Donations
The specific tests done to screen a donor include those 
that play a role in metabolic function and the digestive 
system in particular. Some of these include a complete 
blood count, as well as a c-reactive protein test which 
checks for inflammation within the body. In addition, 
they are tested for levels of creatinine and liver enzymes. 
The stool itself is screened for ova and parasites and C. 
difficile in particular, among other intestinal pathogens 
(Satokari et al, 2015).
Methods of Preparing Feces for Transplantation
The transferring of feces can be done by different proce-
dures. Those include transplantation with an oral capsule, 
colonoscopy or by enema. (Kao et al, 2017). There is also 
debate about whether it makes a difference if the feces 
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were previously frozen, or if fresh stool is used. Results of 
trials show that there is little difference in effectiveness 
between these methods. Therefore, it is suggested that 
frozen samples be used simply because they are easier to 
produce and obtain (Satokari et al, 2015).
In addition to what was mentioned above, using frozen 
stool allows for universal donors. That means that when 
a potential donor is screened and found to be a good 
candidate, his feces can be used for multiple patients. This 
would also allow clinics to store the frozen feces and use 
them as needed (Satokari et al, 2015).
Fresh Stool for FMT
When using fresh stool for FMT, the stool must be used 
within a 6-hour window of time, from defecation to trans-
plantation. With this method, approximately 30 grams of 
stool is mixed with 150 ml of tap water and then admin-
istered to the patient within 15 minutes of preparation. 
This method is very limiting, and not as readily available 
as frozen stool (Satokari et al, 2015).
Preparing Fecal Slurry for Colonoscopy with 
Frozen Stool
There are slight variations in methods of preparing frozen 
stool for FMT. The following is one of them:
Fresh stool is collected and stored in units of 80-100 g. To 
each collection, 200 ml of .9% saline is added. The result-
ing mixture is filtered through a stomacher bag, designed 
to keep samples uncontaminated, yielding 180 ml of fecal 
slurry. Mixing the slurry with 20 ml of 100% glycerol al-
lows it to be frozen at -70 degrees Celsius for 2 months, 
until needed.  For use, the slurry is defrosted overnight at 
4 degrees Celsius and then reconstituted with 160 ml of 
.9% saline. (Kao et al, 2017)
In using fresh or frozen stool, one method of admin-
istering it is through a biopsy channel, a piece of flexible 
tubing in the cecum (Satokari et al, 2015).
Preparing Feces for Capsule Manufacturing
Forty ml of 100% glycerol is added to 200 ml of prepared 
fecal slurry and centrifuged for 20 minutes at room tem-
perature and 400 G (gravitational force). After decanting 
the supernatant, the sample is then centrifuged at 4-8 de-
grees Celsius and 10,000 G by high speed centrifuge. The 
remainder of the sample is mixed to yield about 12 ml of 
sample containing 10^13 microbes by estimation. This is 
then pipetted into size No. 1 gelatin capsules which are 
then encapsulated twice by size 0 and then 00, yielding 
40 capsules. These capsules are then flash frozen at -55 
degrees Celsius on dry ice to preserve them. Just like the 
fecal slurry, the capsules can remain stored at -70 degrees 
Celsius for 2 months. To administer FMT, the patient swal-
lows approximately 40 capsules within a short period of 
time (Kao et al, 2017).
Synthetic FMT
Vos W.M writes that synthetic FMT is likely a good alter-
native to the common use of donor stool. Synthetic FMT 
is a lab produced combination of the needed strains of 
bacteria, without the actual stool of the donor. The reason 
for this is because by the time the donor stool reaches the 
patient, many of the organisms are no longer viable. In ad-
dition, stool contains other wastes, mucus and pathogens. 
Vos suggests that administering synthetic microbiota which 
was cultured to get the right composition of bacteria is not 
only more effective, but less likely to have adverse effects 
as well. Synthetic FMT would not contain all the parts of 
the stool that are unnecessary as well as detrimental to the 
patient. In addition, it would allow for greater viability and 
microbial diversity as well as being able to be manufactured 
and reproduced (Vos, 2013).
Effectiveness in Treating C. difficile Infections
In order to determine effectiveness, a DNA sequencing 
test is performed to determine which bacteria were col-
onized in the gut of the patient post FMT treatment. In 
studies that were done, the patients who were treated 
with heterologous stool samples- that of a donor showed 
a greater diversity in stool microbiology than those who 
were treated with autologous samples- their own, i.e. 
the placebo group. In the heterologous stool samples, 
there was a significantly higher presence of Bacteroidetes 
and firmicutes, indicating that these are the phyla that 
should be present in healthy stool. In contrast, those who 
were treated by placebo did not contain an abundance 
of these bacteria. Instead, they presented with more of 
the Clostridium XIVa clade and Holdemania bacteria 
that were thought to take part in causing the C. difficile 
infection. Results from this study seem to imply that a 
complete engraftment- proliferation of all the bacteria, is 
not necessary so long as the needed bacteria are present. 
(Staley, et all ,2016)
In a systematic review by Cammarota, Laniro, and 
Gasbarrini, A. indicates an 87% success rate when com-
paring the data of numerous studies. The rates of diarrhea 
resolution varied depending on the site of the fecal trans-
plantation. The data indicated a rate of 81% in the stom-
ach, 86% in the duodenum-jejunum, 93% in the cecum-as-
cending colon, and 84% in the distal colon. (Cammarota, 
et al, 2014)
A randomized trial was performed on 46 patients with 
3 recurring episodes of C. difficile. All of these patients 
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were treated with vancomycin without success. During 
the study, all the patients were treated by colonoscopy. 
Some of the patients were treated with donor stool, 
while others were treated with their own autologous 
stool. Those treated with autologous stool were checked 
to determine if the donor stool was indeed more effec-
tive, or similar to the placebo effect. Of the 22 who were 
treated with donor stool, 20 had a full recovery from C. 
difficile, accounting for a 90.9% recovery rate. In contrast, 
of the 24 who were treated with their own stool, only 15 
recovered, which is a 62.5% recovery rate. The patients 
who contracted another C. difficile infection following 
FMT with autologous stool were subsequently treated 
with donor stool, with success. The outcome of this study 
seems to indicate that FMT is a safe, effective way to treat 
recurrent C. difficile infections (Kelley et al, 2016)
A study was done to determine whether transplanta-
tion by colonoscopy or by oral capsule was more efficient. 
The outcome of the study seems to indicate that neither 
one is preferable and both were effective. The factors to 
consider were those that an oral capsule is both less inva-
sive and cheaper to administer. (Kao et al, 2017) 
FMT for Ulcerative Colitis
Ulcerative colitis is a condition in which the mucosal 
layer of the colon is inflamed. Patients with this condi-
tion present with bloody stool, anemia and abdominal 
pain (Costello et al, 2019). A trial was done in 3 hospitals, 
treating 85 patients to see if FMT could work to cure ul-
cerative colitis in addition to the known effects of treating 
C. difficile infections. In this trial, patients were treated 
with stool from multiple donors to increase the biodiver-
sity. There was also a placebo group. In both groups color 
and odor was added so that the patients would not know 
if they were receiving the real transplant. The original in-
fusion was administered by colonoscopy, directly into the 
terminal ileum and caecum. The patients were monitored 
periodically for 8 weeks (Paramsothy et al., 2017).
Though there was not a significant majority, 27% of 
people who received donor FMT saw a relief of symp-
toms, while only 8% of placebo patients saw these effects. 
After the 8 weeks however, the numbers on both sides 
increased. It was observed that a particular bacterium of 
the Fusobacterium variety was present in those who did 
not have a remission of symptoms after FMT. It is import-
ant to note that majority of the patients in the placebo 
group had milder symptoms to begin with. The outcome 
of the study indicated that FMT may be a good alterna-
tive to usual steroidal therapies used for ulcerative colitis, 
though more research would need to be done to deter-
mine if that is indeed the case (Paramsothy et al., 2017).
A study was done to determine if anaerobically pre-
pared stool would be as effective as aerobically prepared 
FMT for ulcerative colitis. The purpose of the trial was to 
determine if the organisms in the stool would be more 
viable if they were prepared anaerobically. This study was 
done after the study mentioned above by Paramsothy. 
Based on data that was collected from the above study, 
researchers were hopeful that FMT could be very effec-
tive in ulcerative colitis patients. This study was a varia-
tion of the first one. The outcome of the study indicated 
that 32% of those who received donor FMT saw an initial 
relief of symptoms. Nine percent of those who received 
autologous stool saw an initial relief of symptoms as well. 
(Costello et al, 2019). This data seems to be very similar 
to that of the aerobically prepared FMT. More trials would 
be needed to determine if anaerobically prepared stool is 
actually more effective. This study adds to the research 
that FMT is helpful in some cases for ulcerative colitis. 
FMT for IBD
IBD is a general term for different inflammatory bowel dis-
eases. Included in these are ulcerative colitis and Crohn’s 
disease. As mentioned above, these diseases cause chron-
ic inflammation of the bowel. Either of these conditions 
can cause colorectal cancer, and other medical problems 
in the individual. There is evidence that suggests that it is 
the microbiome gut composition that plays a role in these 
diseases. After seeing great success in treating recurrent 
C. difficile with FMT, researchers are hopeful that it can 
work as a therapeutic treatment for other conditions as 
well (Quraishi et al., 2017).
According to studies, it seems that IBD can be an ab-
normal reaction to having microbiota in the gut. Patients 
with this condition possess genes that view these enteric 
bacteria as pathogens, even those that are considered 
symbiotic in a healthy person. Evidence to support this 
study included testing on germ-free animal models that 
were predisposed to IBD. In addition, there were stud-
ies done in which the fecal stream was diverted. In both 
of these studies, it appeared that not having any bacteria 
present in the gut led to having no inflammatory symp-
toms. The activation of innate and adaptive immunity by 
bacteria that is normally nonpathogenic can lead to an 
inflammation in the gut in the absence of pathogenic bac-
teria (Quraishi et al., 2017).
It is noted by Quraishi et al., that though it seems that 
any presence of bacteria induces IBD in those that are pre-
disposed, there are studies done that suggest that there 
is indeed a difference in microbial diversity in those with 
IBD in comparison to those with a healthy gut (Quraishi et 
al, 2017.) The composition is characterized by an increase 
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in bacteria which include Enterobacteriaceae, Pasteurella, 
Veillonella, and Fusobacteria, and also contains less Firmicutes, 
Bacteroidetes, and Clostridia (Gevers et al., 2014). It is also 
noted that there is an increase of Proteobacteria in those 
with IBD. Using FMT with IBD has been met with very lim-
ited success in the past. There has been more evidence of 
success with ulcerative colitis patients, than in those with 
Crohn’s disease (Quraishi et al, 2017).
FMT for Hepatic Myelopathy
Hepatic myelopathy is a neurological complication that 
comes from severe liver disease. Usually, it can only be 
treated by a liver transplant. There was a case study done, 
however, that indicated that FMT may indeed be a solu-
tion to this illness. The study was done on one 45-year-
old woman in china. She was admitted to the hospital 
numerous times, and underwent various procedures. The 
reasons for these included different complications such as 
splenomegaly, vomiting blood and other internal bleeding. 
The last visit was due to a weakness and stiffening in her 
legs. Interestingly, after being treated with 3 courses of 
FMT, she reported a relief of symptoms. There is no con-
clusive evidence that this can work in all cases. However, 
due to the known correlation between gut symbiosis and 
neurological health, the researchers say that FMT may be 
a good therapeutic alternative to a liver transplant as it is 
more available and less invasive (Sun et al, 2019).
Adverse Effects of FMT
In a randomized trial done, it was noted that there were 
no serious adverse effects following fecal microbiota 
transplantation. The study did not include anyone who 
was immunocompromised, or above age 75. Following 
FMT the patients were monitored periodically for 6 
months, and none exhibited any serious symptoms in re-
lation to FMT (Kelley et al, 2016).
Kao et al reports that two patients died following FMT, 
though it was not likely due to the procedure. Both had 
significant cardio-pulmonary disorders and both were el-
derly (Kao et al, 2017).
While FMT has seems to have many beneficial uses, 
as with any therapy, there are downsides as well. Dr. 
Schwartz, Gluck and Koon say that a reason for this may 
be because though fecal donors go through extensive 
screening, it is possible that they were carrying diseases 
that they were unaware of. They could have been asymp-
tomatic and not have been tested for that specific patho-
gen. There were two cases noted of norovirus in Virginia 
Mason Medical Center in Seattle. Norovirus is a common 
contagious virus that causes gastroenteritis in many peo-
ple. In those cases, the donors were asymptomatic and it 
was unknown whether the virus was transmitted through 
the feces as there was a window of time between the 
collection of the feces and the actual transplantation. The 
most significant effect of these cases was that both pa-
tients presented with a relapse of C. difficile infections. 
It was speculated that it is possible that the norovirus 
altered the bacterial community present in healthy stool 
resulting in an ineffective FMT (Brandt, L. J., 2013). 
In an FMT trial on ulcerative colitis patients, a significant 
amount reported adverse effects. Approximately 78% of 
the donor stool recipients and 83% of the placebo recipi-
ents reported gastrointestinal upset. The complaints were 
self-limiting, resolving on their own and having no long-
term effects. In addition, 2 patients who received donor 
stool, and 1 who received autologous stool as a placebo 
presented with serious adverse effects (Paramsothy et al, 
2017). The study did not mention what they were.
Quraishi et al. note that FMT should not be admin-
istered to those who have Crohn’s disease with deep 
patch ulceration in the gut. The reason for this is because 
it is likely that the bacteria may translocate. That is, the 
bacteria may cross the organ barrier and enter into the 
bloodstream where it does not belong. Administering 
FMT in those patients could cause many harmful effects. It 
is different however for ulcerative colitis because in that 
condition the inflammation is contained to the epithelium 
and risk of bacterial translocation is not high (Quraishi et 
al., 2017).
In a letter written to the editor of The American 
Journal of Gastroenterology, Dr. Brandt presents his ob-
servations that there are effects of C. difficile that are not 
yet known. He noted however that it is reasonable to as-
sume that down the line there would be adverse effects. 
Those may include short term affects like allergic reac-
tions or transmitted infections. He speculates that it is 
likely that FMT patients may suffer long term effects such 
as conditions that result from an altering the recipient’s 
microbiome to be similar to that of the donor (Brandt, L. 
J., 2013). It is interesting to note, however, that this was 
written in 2013, and articles written in later years did not 
report these predictions.
Why Not Oral Probiotics?
People think that probiotics are helpful for the gut mi-
crobiome. The reason for this assumption is that if some 
bacteria are considered good, an increase in those bac-
teria should be considered helpful to a person’s overall 
wellbeing. Research has shown, however, that this may 
not necessarily be the case. It was noticed that certain 
cancer patients were not responding to immunotherapy 
and that majority of those patients were taking probiotic 
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supplements. There is evidence that taking a probiotic 
supplement reduces the biodiversity in the gut. Though it 
does cause an increase in certain essential bacteria, those 
bacteria in large quantities may be harmful to other sys-
tems. For example, an increase in Bacteroides is said to 
increase metabolism, but seems to be detrimental to the 
immune system (Hardy, L., 2019).
There is also research that indicates that taking pro-
biotics after a course of antibiotics actually slowed the 
body’s response in replenishing the gut. In this study, three 
groups of patients were given antibiotics. One group was 
not subsequently treated, another was given probiotics, 
and the third was given autologous FMT with stool col-
lected before they were given antibiotics. Evidence from 
this study indicated that those who were given probiotic 
supplements took significantly longer to recover than the 
others. This study also seems to show that FMT is indeed 
a good way to replenish the gut bacteria after treatment 
with antibiotics (Hardy, L., 2019).
Conclusion
In conclusion, there is hope that FMT can effectively treat 
dysbiosis of the gut. This is especially true for the case 
of a recurrent Clostridium difficile infection, where the 
majority of cases were cured with few or no adverse 
effects noted. There are studies that imply that other gas-
trointestinal diseases could be treated effectively as well. 
It was also noted that there is little difference in outcome 
of treatment when different methods of transplantation 
are used. Other than for recurrent C. difficile infections 
for which FMT has been deemed effective, more research 
should be done to determine if it is effective for the other 
mentioned diseases. Overall, FMT is a promising and in-
novative therapy for gastrointestinal problems.
References
Blaut, M., Collins, M., Welling, G., Doré, J., Van Loo, J., & 
De Vos, W. (2002). Molecular biological methods for 
studying the gut microbiota: The EU human gut flora 
project. British Journal of Nutrition, 87(S2), S203-S211. 
doi:10.1079/BJN/2002539
Brandt, L. J. (2013). FMT: First step in a long journey. The 
American Journal of Gastroenterology, 108(8), 1367-
1368. doi:http://dx.doi.org/10.1038/ajg.2013.165
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014). Fecal 
microbiota transplantation for the treatment of clos-
tridium difficile infection: A systematic review. Journal of 
Clinical Gastroenterology, 48(8), 693.
Costello, S. P., Hughes, P. A., Waters, O., Bryant, R. V., 
Vincent, A. D., Blatchford, P., . . . Andrews, J. M. (2019). 
Effect of fecal microbiota transplantation on 8-week 
remission in patients with ulcerative colitis: A random-
ized clinical trial. Jama, 321(2), 156-164. doi:10.1001/
jama.2018.20046
Hardy, L. (2019, Nov 26). Why taking probiotics could be 
bad for your health [eire region]. Daily Mail  
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, 
Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., 
Song, S. J., Yassour, M., Morgan, X. C., Kostic, A. D., Luo, 
C., González, A., McDonald, D., Haberman, Y., Walters, 
T., Baker, S., Rosh, J., Stephens, M., … Xavier, R. J. (2014). 
The treatment-naive microbiome in new-onset Crohn’s 
disease. Cell host & microbe, 15(3), 382–392. https://doi.
org/10.1016/j.chom.2014.02.005
Kao, D., Roach, B., Silva, M., Beck, P., Rioux, K., Kaplan, G. 
G., . . . Louie, T. (2017). Effect of oral capsule– vs colo-
noscopy-delivered fecal microbiota transplantation on 
recurrent clostridium difficile infection: A randomized 
clinical trial. Jama, 318(20), 1985-1993. doi:10.1001/
jama.2017.17077
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., 
Atreja, A., Moore, T., & Wu, G. (2015). Update on 
Fecal Microbiota Transplantation 2015: Indications, 
Methodologies, Mechanisms, and Outlook. 
Gastroenterology, 149(1), 223–237. https://doi.
org/10.1053/j.gastro.2015.05.008
Kelly, C. R., Khoruts, A., Staley, C., Sadowsky, M. J., 
Abd, M., Alani, M., . . . Brandt, L. J. (2016). Effect of fecal 
microbiota transplantation on recurrence in multiply 
recurrent clostridium difficile infection: A randomized 
trial. Annals of Internal Medicine, 165(9), 609.
Lopetuso, L. R., Scaldaferri, F., Petito, V., & Gasbarrini, A. 
(2013). Commensal Clostridia: leading players in the 
maintenance of gut homeostasis. Gut pathogens, 5(1), 23. 
https://doi.org/10.1186/1757-4749-5-23
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. 
J., van den Bogaerde, J., Samuel, D., ... & Xuan, W. (2017). 
Multidonor intensive faecal microbiota transplantation 
for active ulcerative colitis: a randomised placebo-con-
trolled trial. The Lancet, 389(10075), 1218-1228.
Petrov, M. E. (2011). Autoimmune Disorders: Symptoms, 
Diagnosis, and Treatment. Nova Science Publishers, Inc.
Quraishi, M. N., Critchlow, T., Bhala, N., Sharma, N., & 
Iqbal, T. (2017). Faecal transplantation for IBD man-




Satokari, R., Mattila, E., Kainulainen, V., & Arkkila, P. E. T. 
(2015). Simple faecal preparation and efficacy of frozen 
inoculum in faecal microbiota transplantation for re-
current clostridium difficile infection – an observational 
cohort study. Alimentary Pharmacology & Therapeutics, 
41(1), 46-53. doi:10.1111/apt.13009
Staley, C., Kelly, C. R., Brandt, L. J., Khoruts, A., & 
Sadowsky, M. J. (2016). Complete microbiota engraft-
ment is not essential for recovery from recurrent 
clostridium difficile infection following fecal microbiota 
transplantation. Mbio, 7(6), e01965-16. doi:10.1128/
mBio.01965-16
Sun, L., Li, J., Lan, L., & Li, X. (2019). The effect of fecal 
microbiota transplantation on hepatic myelopathy: A 
case report. Medicine, 98(28), e16430. doi:10.1097/
MD.0000000000016430
Tortora, G. J., & Derrickson, B. (2014). Principles of 
anatomy and physiology. Hoboken, NJ: Wiley.
Vos, W. M. (2013). Fame and future of faecal transplan-
tations – developing next-generation therapies with 
synthetic microbiomes. Microbial Biotechnology, 6(4), 
316-325. doi:10.1111/1751-7915.12047
Weingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., 
Nelson, V. M., … Khoruts, A. (2014). Microbiota trans-
plantation restores normal fecal bile acid composition 
in recurrent Clostridium difficile infection. American 
Journal of Physiology-Gastrointestinal and Liver 
Physiology, 306(4). doi: 10.1152/ajpgi.00282.2013
Zeng, W., Shen, J., Bo, T., Peng, L., Xu, H., Nasser, 
M. I., Zhuang, Q., & Zhao, M. (2019). Cutting Edge: 
Probiotics and Fecal Microbiota Transplantation in 
Immunomodulation. Journal of immunology research, 
2019, 1603758. https://doi.org/10.1155/2019/1603758
